1. Kinetics and Quantification of Antibacterial Effects of Beta-Lactams, Macrolides, and Quinolones against Gram-Positive and Gram-Negative RTI Pathogens

   • K.-J. Schaper
   • S. Schubert
   • A. Dalhoff

   Supplement Article Pages: 3 - 14

2. Pharmacodynamics of Moxifloxacin and Levofloxacin Simulating Human Serum and Lung Concentrations*

   • S. Schubert
   • A. Dalhoff
   • U. Ullmann

   Supplement Article Pages: 15 - 21

3. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Once-Daily Treatment Using Ciprofloxacin in an Extended-Release Dosage Form*

   • E. L. Schuck
   • A. Dalhoff
   • H. Derendorf

   Supplement Article Pages: 22 - 28

4. The Integrated Use of Pharmacokinetic and Pharmacodynamic Models for the Definition of Breakpoints

   • H. Stass
   • A. Dalhoff

   Supplement Article Pages: 29 - 35

5. Effect of pH on the in Vitro Activity of and Propensity for Emergence of Resistance to Fluoroquinolones, Macrolides, and a Ketolide

   • A. Dalhoff
   • S. Schubert
   • U. Ullmann

   Supplement Article Pages: 36 - 43

6. Contribution of Immunocompetence to the Antibacterial Activities of Ciprofloxacin and Moxifloxacin in an in Vitro Pharmacodynamic Model*

   • A. Dalhoff

   Supplement Article Pages: 44 - 49

7. Moxifloxacin and Ciprofloxacin Protect Human Respiratory Epithelial Cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in Vitro

   • M. Ulrich
   • J. Berger
   • G. Döring

   Supplement Article Pages: 50 - 54

8. Immunomodulatory Activities of Fluoroquinolones

   • A. Dalhoff

   Supplement Article Pages: 55 - 70